A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Fomepizole

Antidote class · 4 generic manufacturers · 4 ANDAs filed at FDA.

First FDA approval2012-10-09
Generic availableYes · 4 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Fomepizole used for?

Fomepizole is a Antidote medication tracked in Medicare Part D.

Is there a generic for Fomepizole?

Yes. 4 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Fomepizole?

NADAC pricing data not currently available for this drug.

Is Fomepizole on the FDA shortage list?

No. Fomepizole is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Antidote2 alternatives in D1
01
Acetylcysteine
Brand: ACETADOTE
$0.643Lowest NADAC
13Generic mfrs
$3.0MCY24 Part D spend
Compare →
02
Hydroxocobalamin
Brand: Cyanokit
$0.814Lowest NADAC
1Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (4 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.